On March 7, 2016, Judge Eldon E. Fallon issued an order that confirmed the 40 Xarelto lawsuits that were selected during the discovery pool against the makers of Xarelto.
These multijurisdictional and so-called “bellwether trials,” will help in determining the reaction from jurors to those cases. Depending on the outcome of those first few cases, the parties may be motivated to go back to the table for settlement negotiations. They would also then be ready to consider plaintiff and defendant fact sheets, preservation orders, interactions with prescribing physicians and discovery.
Xarelto (rivaroxaban) was approved by the FDA in July of 2011 as a preventative of blood clots in patients who were going through hip and knee replacement surgery. It was touted by the manufacturers as a “newer generation” anticoagulant, and they claimed it was superior to the drug warfarin because it didn’t require patients to alter their diet or to be monitored for blood clotting as they did while on warfarin.
Later, Xarelto was approved for use to prevent stroke in patients with non-valvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis. Since its 2011 release onto the market, however, Xarelto has been linked to hundreds of incidents of adverse reactions to the drug including blood clots, excessive gastrointestinal bleeding and even the death of patients.
The Institute of Safe Medicine Practices QuarterWatch publication listed Xarelto as having a total of 356 cases of serious, disabling problems linked to, including severe blood clots in younger patients taking the drug after hip and knee replacement surgery just one year after its initial release on the marketplace.
By far, the most dangerous cause for concern for patients and their families is that it appears there is no antidote to the drugs’ effects as an anticoagulant. For those patients who experience excessive bleeding, the dangers of taking Xarelto can be extremely serious or potentially fatal.
For patients that needed an effective anticoagulant drug, Xarelto seemed to be a better choice than having to take warfarin, which needed to be monitored constantly for potential clotting and patients, were required to change their diets as well.
But what patients and their doctors were unaware of that in the event of a serious bleeding event, unlike warfarin, where an infusion of vitamin K could reverse the effects, with Xarelto, that antidote would not work – and there were no other known antidotes for the effects of Xarelto.
If you or a loved one has been harmed by taking Xarelto, contact a Xarelto Lawsuit Attorney at John Foy & Associates to set up a free consultation. Call us at (404) 800-4635.